Skip to content

UK edition London open

Markets

  • FTSE 10010,663.55-0.25%
  • S&P 5007,340.53-1.03%
  • GBP/USD1.3174-0.08%
  • EUR/USD1.0975-0.21%
  • Brent$89.42-3.99%
  • Gold$3,772.20-2.38%
  • Bitcoin$64,246-1.00%

Delayed · 10:48 UK

British Business Bank life sciences backing passes £1bn as fund commitments reach £832m

The British Business Bank's life sciences backing has reached £1.13bn, with £832m in fund commitments and £302m invested directly in 28 scale-ups.

The British Business Bank said on Wednesday its backing for UK life sciences has reached £1.13bn, with fund commitments of £832m, up from £560m in December 2025.

The total is made up of £832m committed across 20 specialist funds and £302m invested directly in 28 scale-ups (young companies raising later-stage funding), half of them university spinouts. The figures are the Bank’s own and are as at end March 2026.

On direct investment, the Bank had put £180m into 19 companies when it reported on 13 November 2025. It began investing directly in 2021. Its largest single stake to date is £25m in Alchemab Therapeutics.

On funds, the Bank reported £560m across 15 funds when it agreed a $100m commitment to SV Health Investors’ SV8 Biotech fund on 8 December 2025. By 24 September 2026 the figure was more than £745m across 17 funds.

The Bank also announced a €58m commitment to Sofinnova Crossover Fund II, a late-stage growth fund. It follows an earlier commitment to the manager’s Sofinnova Capital XI.

Leandros Kalisperas, chief investment officer at the Bank, said:

“The Bank is here to back British science.”

He said the Bank supports specialist fund managers and invests directly in high-growth companies to help scientists turn research into commercial success.

The Bank is due to launch the British Growth Partnership, which will invest third-party capital from pension funds into growth-stage UK companies.

The Bank said in November 2025 that it will commit £4bn of new capital across the eight sectors of the government’s Industrial Strategy, including life sciences.

The same month it said its Life Sciences Investment Programme, which makes cornerstone commitments (anchor investments that help a fund reach its first close) to later-stage funds, had £100m left to allocate. It expected to deploy that within four to six months.

An evaluation by Ipsos UK found strong evidence that the programme added to fund-raising at fund level. The programme had committed £150m and its funds had secured a further £689m from private investors, against a target of £400m.

Christine Hockley, managing director and co-head of funds at the Bank, said in November 2025 that the funding gap “has historically led promising UK firms to relocate or accept sub-optimal exits”.

Mark Andrews, senior director for life sciences at the Bank, said in September that UK life science companies “remain undercapitalised relative to their potential”.

The £832m of fund commitments has brought in £3.1bn of private sector leverage, meaning private money raised alongside the Bank’s. That is over £3 for every pound invested.

In December 2025, £560m of commitments had leveraged £3.04bn, which the Bank put at six pounds for every pound invested.

Professor Chris Molloy, chief executive of the BioIndustry Association, said the Bank “plays a welcome and vital role to turn world-class science into breakthrough medicines, skilled jobs and long-term value for taxpayers”.

Published by Financial News

Written by

Declan Wraight

Declan Wraight spent the better part of a decade in and around private capital before he started filing copy. He read PPE at Trinity College Dublin, joined a Big Four transaction services group in London out of school, and learned how a leveraged cap table actually works by chasing covenant compliance for two years. He moved to corporate development at…

More from Declan Wraight